carisoprodol + aspirin + codeine

Carisoprodol + aspirin + codeine is a fixed-dose combination pharmaceutical product that was primarily marketed under the brand name Soma Compound with Codeine. It integrates three distinct pharmacological agents: carisoprodol, a centrally-acting skeletal muscle relaxant; aspirin, a nonsteroidal anti-inflammatory drug (NSAID); and codeine phosphate, an opioid analgesic. Carisoprodol is thought to exert its effects by modulating GABAergic transmission in the central nervous system, while aspirin irreversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2) to reduce prostaglandin synthesis. Codeine acts as an agonist at mu-opioid receptors, altering the perception of and emotional response to pain. Indicated for the short-term treatment of acute, painful musculoskeletal conditions, the drug was typically used as an adjunct to rest and physical therapy. Due to the potential for abuse and the presence of both carisoprodol and codeine, it is classified as a Schedule III controlled substance. The product has been discontinued in the United States market, although its individual components remain available as separate entities.

Brand names

Soma Compound with Codeine

Other names

carisoprodol, aspirin, and codeine phosphate tablets